Technical Analysis for ALXO - ALX Oncology Holdings Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical ALXO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.66% | |
| Multiple of Ten Bearish | Other | 0.66% | |
| Wide Bands | Range Expansion | 0.66% | |
| Below Lower BB | Weakness | 0.66% | |
| Lower Bollinger Band Touch | Weakness | 0.66% | |
| Fell Below 20 DMA | Bearish | -8.53% | |
| 180 Bearish Setup | Bearish Swing Setup | -8.53% | |
| Multiple of Ten Bearish | Other | -8.53% | |
| Wide Bands | Range Expansion | -8.53% | |
| Crossed Above 20 DMA | Bullish | -19.19% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 5 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Myelodysplastic Syndrome Epidermal Growth Factor Receptor Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Myelodysplastic Syndrome Epidermal Growth Factor Receptor Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 117.45 |
| 52 Week Low | 28.01 |
| Average Volume | 269,674 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 75.88 |
| 20-Day Moving Average | 69.94 |
| 10-Day Moving Average | 69.54 |
| Average True Range | 5.76 |
| ADX | 16.48 |
| +DI | 14.98 |
| -DI | 30.37 |
| Chandelier Exit (Long, 3 ATRs ) | 65.72 |
| Chandelier Exit (Short, 3 ATRs ) | 75.01 |
| Upper Bollinger Band | 81.57 |
| Lower Bollinger Band | 58.31 |
| Percent B (%b) | -0.02 |
| BandWidth | 33.26 |
| MACD Line | -2.74 |
| MACD Signal Line | -2.20 |
| MACD Histogram | -0.535 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 67.07 | ||||
| Resistance 3 (R3) | 68.01 | 65.92 | 65.55 | ||
| Resistance 2 (R2) | 65.92 | 63.59 | 65.45 | 65.04 | |
| Resistance 1 (R1) | 61.93 | 62.16 | 60.89 | 60.99 | 64.54 |
| Pivot Point | 59.84 | 59.84 | 59.31 | 59.37 | 59.84 |
| Support 1 (S1) | 55.85 | 57.51 | 54.81 | 54.91 | 51.36 |
| Support 2 (S2) | 53.76 | 56.08 | 53.29 | 50.86 | |
| Support 3 (S3) | 49.77 | 53.76 | 50.35 | ||
| Support 4 (S4) | 48.83 |
